(Q42677492)

4 November 2017

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial (English)

1 reference

4 November 2017

phase III clinical trial

0 references

1 reference

1 reference

1 reference

1 reference

Josep Tabernero Caturla

4

1 reference

4 November 2017

7

1 reference

4 November 2017

Stephen Clarke

5

1 reference

ORCID Public Data File 2021

Seock-Ah Im

11

object named as

Seock-Ah Im

1 reference

4 November 2017

Aimery de Gramont

1

1 reference

4 November 2017

Eric Van Cutsem

2

1 reference

4 November 2017

Hans-Joachim Schmoll

3

1 reference

4 November 2017

Malcolm J Moore

6

1 reference

4 November 2017

Thomas H Cartwright

8

1 reference

4 November 2017

J Randolph Hecht

9

1 reference

4 November 2017

Fernando Rivera

10

1 reference

4 November 2017

György Bodoky

12

1 reference

4 November 2017

Ramon Salazar

13

1 reference

4 November 2017

Frédérique Maindrault-Goebel

14

1 reference

4 November 2017

Einat Shacham-Shmueli

15

1 reference

4 November 2017

Emilio Bajetta

16

1 reference

4 November 2017

Martina Makrutzki

17

1 reference

4 November 2017

Aijing Shang

18

1 reference

4 November 2017

Thierry André

19

1 reference

4 November 2017

Paulo M Hoff

20

1 reference

4 November 2017

16 November 2012

1 reference

Lancet Oncology Commission

4 November 2017

1 reference

4 November 2017

13

1 reference

4 November 2017

12

1 reference

4 November 2017

1225-1233

1 reference

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

On closed testing procedures with special reference to ordered analysis of variance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

1 reference

7 January 2021

Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Mechanisms of resistance to topoisomerase I-targeting drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Induction of angiogenesis during the transition from hyperplasia to neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Molecular mechanisms underlying tumor dormancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970509-0

7 January 2021

10.1016/S1470-2045(12)70509-0

Identifiers

DOI

1 reference

4 November 2017

1 reference